The drug is being developed for heart failure. This is the first study in patients with stable heart failure .
Conditions
Interventions
Product Name: CK-1827452
Product Code: CK-1827452
Pharmaceutical Form: Intravenous infusion
Current Sponsor code: CY 1121
Other descript
Sponsors
Cytokinetics, Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patient is male, or female of non-childbearing potential (two years post-menopausal or surgically sterilised) 2.Female patients must have a negative urine pregnancy test prior to entry into the study 3.Patient is 18 years old or greater 4.Patient has given signed informed consent 5.Patient is considered to be in suitable health in the opinion of the investigator, as determined by: - A pre-study physical examination with no clinical abnormalities which in the opinion of the investigator would preclude participation in the study other than physical symptoms or signs consistent with stable heart failure - An ECG with no abnormalities in the opinion of the investigator that would impair assessment of stopping criteria 6.Patient has pre-study clinical laboratory findings that are within normal range, or if outside of the normal range, should not preclude participation in the study in the opinion of the investigator (see Exclusion Criteria, below, for exceptions) 7.Patient has a documented diagnosis of heart failure with an ejection fraction of less than 40%, except for Cohort 4, where ejection fraction must be less than or equal to 30% 8.Patient has been on a stable dose of a beta blocker and an ACE inhibitor (or an ARB) for at least 4 weeks. If prescribed, diuretics must have been administered according to a consistent regimen for at least 4 weeks. 9.Patient is currently in sinus rhythm 10.Patient has interpretable echocardiographic images on a screening echocardiogram Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Patient has been hospitalised for heart failure, myocardial infarction, coronary revascularisation, or another cardiac indication within the last 6 weeks 2. Patient has a current history of alcohol use which in the opinion of the investigator would preclude participation in the study 3. Patient has a current history of drug abuse 4. Patient has donated blood or blood products within 30 days prior to screening 5. Patient has CCS Class III or IV angina 6. Patient has significant obstructive valvular disease or significant congenital heart disease 7. Patient has had a valve replacement 8. Patient is pacemaker dependent 9. Patient is on chronic anti-arrhythmic therapy, with the exception of amiodarone 10. Patient is currently taking, or has taken in the last 7 days, a CYP3A4 inhibitor or inducer medication listed in Appendix C 11. Patient has a history of hypertrophic obstructive cardiomyopathy 12. Patient weighs > 120 kg 13. Patient has a supine resting systolic blood pressure 160 mmHg after 3 minutes rest 15. Patient has a supine resting diastolic blood pressure > 100 mmHg after 3 minutes rest 16. Patient has a supine resting heart rate = 100 beats per minute after 3 minutes rest 17. Patient has an Modification of Diet in Renal Disease (MDRD) estimate of GFR = 35 ml/min/1.73 m2 (see Appendix D) 18. Patient has a potassium 5.5 mEq/L 19. Patient has a sodium = 133 mEq/L 20. Patient has a urea > 15 mmole/L 21. Patient has a troponin I or T at screening that is detectable at the investigative site’s clinical laboratory 22. Patient has a haemoglobin 3 times the upper limit of normal 24. Patient is, in the opinion of the investigator, not suitable to participate in the study 25. Patient has participated in any clinical study with an investigational drug within three months prior to the first day of dosing with the exception of coronary stent studies 26. Patient has ever received CK-1827452
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Main Objective: •To evaluate the safety and tolerability of CK-1827452 Injection administered as an intravenous infusion to stable heart failure patients. ; Secondary Objective: •To establish a relationship between plasma concentration and pharmacodynamic effect for CK 1827452 Injection. •To determine the pharmacokinetics of CK-1827452 Injection in stable heart failure patients. ;Primary end point(s): To determine the pharmacokinetics of CK-1827452 injection in stable heart failure patients. | — |
Countries
United Kingdom
Outcome results
None listed